Trial Profile
Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Thrombosis
- Focus Therapeutic Use
- Acronyms RIPORT
- 26 Jun 2021 Results presented at The International Liver Congress 2021
- 09 Mar 2020 Status changed from active, no longer recruiting to completed.
- 18 May 2018 Status changed from recruiting to active, no longer recruiting.